Measurement properties and interpretation of three shortened versions of the asthma control questionnaire
Measurement properties and interpretation of three shortened versions of the asthma control questionnaire
复制标题
DOI：
10.1016/j.rmed.2004.10.008
复制
发表时间：
2005-05-01
影响因子：
4.3
通讯作者：
Ståhl, E
中科院分区：
文献类型：
--
作者：
Juniper, EF;Svensson, K;Ståhl, E
哮喘控制问卷 (ACQ) 衡量国际指南确定的哮喘治疗的充分性。它由七个项目组成（5 x 症状、救援支气管扩张剂的使用和 FEV1% 预测正常值）。一项验证研究表明，在临床研究中，可能不需要测量 FEV1 和支气管扩张剂的使用，但这从未在临床试验中进行过正式测试。该分析的目的是 (1) 检查三种缩短版本的 ACQ（无症状症状、症状加 FEV1 和症状加短效 β(2) 激动剂）的测量特性，以及 (2) 确定使用缩短版本是否会改变临床试验的结果。在随机试验中，552 名成年人在基线时以及治疗 13 周和 26 周后完成了 ACQ。分析表明，ACQ 的所有四个版本的测量特性都非常相似。原始 ACQ 和简化版本之间的一致性很高（组内相关系数：0.94-0.99）。 ACQ 和缩短版本之间的平均差异小于 0.04（7 分制）。使用四个版本的临床试验结果几乎相同，平均治疗差异范围为 -0.09 (P = 0.17) 至 -0.13 (P = 0.07)。就可解释性而言，所有四个版本的最小重要差异均接近 0.5。总之，ACQ 的这三个缩短版本可以用于大型临床试验，而无需牺牲有效性或改变解释。 (c) 2004 Elsevier Ltd. 保留所有权利。
The Asthma Control Questionnaire (ACQ) measures the adequacy of asthma treatment as identified by international guidelines. It consists of seven items (5 x symptoms, rescue bronchodilator use and FEV1% of predicted normal). A validation study suggested that in clinical studies measurement of FEV1 and bronchodilator use may not be need-ad but this has never formally been tested in a clinical trial. The aims of this analysis were (1) to examine the measurement properties of three shortened versions of the ACQ (symptoms atone, symptoms plus FEV1 and symptoms plus short-acting beta(2)-agonist) and (2) to determine whether using the shortened versions would alter the results of a clinical trial. In the randomised trial, 552 adults completed the ACQ at baseline and after 13 and 26 weeks of treatment. The analysis showed that the measurement properties of all four versions of the ACQ are very similar. Agreement between the original ACQ and the reduced versions was high (intraclass correlation coefficients: 0.94-0.99). Mean differences between the ACQ and the shortened versions were less than 0.04 (on the 7-point scale). Clinical trial results using the four versions were almost identical with the mean treatment difference ranging from -0.09 (P = 0.17), to -0.13 (P = 0.07). For interpretability, the minimal important difference for all four versions was close to 0.5. In conclusion, these three shortened versions of the ACQ can be used in large clinical trials without toss of validity or change in interpretation. (c) 2004 Elsevier Ltd. All rights reserved.